IDO1 expression in tumors, including breast cancer, is often associated with a worse prognosis, since IDO1 and its metabolites inhibit anti-cancer immune defenses and facilitate the survival, motility, and chemoresistance of tumor cells, as well as neo-angiogenesis and metastasis [8,11,12,14,24]. Here, IDO1 is linked to cancer.